Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Worldwide, several studies report that 4.4% to 85.4% of thalassemia patients were positive
for anti hepatitis C antibodies. Recently, three different studies reported the efficacy and
the safety of combination therapy with pegylated interferon and ribavirin in thalassemic
patients. This study is carried ahead to assess the impact of combination therapy with
pegylated-interferon and ribavirin in a large cohort of italian patients with beta
thalassemia major - transfused and not transfused, sickle cell disease and
sickle/beta-thalassemia.